| Hazard Information | Back Directory | [Uses]
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001)[1][2][3]. | [in vivo]
Atrosab (i.v., twice weekly, 28 days) has been shown to be effective for inflammatory diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS) in both monkeys and human TNF transgenic/human TNFR1 knock-in mice model and in human TNFR1 knock-in mice (hp55K/i) EAE model [2].
Atrosab (20 mg/kg, i.p.) reduces immune cell infiltrates in humanized TNFR1 knock-in mice [3].
| Animal Model: | CIA rhesus monkey model[2]. | | Dosage: | | | Administration: | i.v., twice weekly, 28 days | | Result: | Reduced of the acute-phase C-reactive protein (CRP) and IL-6 in serum.
Improved the clinical arthritis score, delayed the onset of symptoms, and inhibited cartilage degradation.
|
| Animal Model: | Human TNF transgenic/human TNFR1 Knock-in mice model (Tg197/hp55K/i) for arthritis and human TNFR1 Knock in mice (hp55K/i) EAE model for multiple sclerosis(MS)[2]. | | Dosage: | | | Administration: | i.v., twice weekly, 28 days | | Result: | Significantly reduced arthritic pathology and the underlying histopathological lesions in rheumatoid arthritis (RA) mice.
Abolished the development of paralytic symptoms without affecting the overall health status of the animals in EAE mice model of MS.
Showed to be effective for treatment of inflammatory diseases such as RA and MS.
|
| Animal Model: | humanized TNFR1 knock-in mice[3]. | | Dosage: | 20 mg/kg | | Administration: | i.p., four times (on days 1, 4, 8 and 12 of manifest EAE) | | Result: | Significantly prevented EAE-associated weight loss.
Led less spinal cord demyelination.
Reduced accumulated amyloid precursor protein (APP), a marker of axonal injury.
Reduced numbers of CD3+ T cells, Mac-3+ activated microglia/macrophages and CD45R+ B cells.
Reduced immune cell infiltration.
|
| [References]
[1] Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2(6):639-47. DOI:10.4161/mabs.2.6.13583
[2] Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. DOI:10.4161/mabs.2.6.13583
[3] E. Guenzi, et al. FRI0231 Atrosab, a humanized antibody directed against tnf-receptor 1, hold great promises for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2013 Jun 14; 72(3):A451.
[4] Williams SK, et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018 Sep 11;8(1):13628. DOI:10.1038/s41598-018-31957-7 |
|
|